Spigel DR, et al. - Amrubicin monotherapy has efficacy in relapsed/refractory SCLC. In the current study, amrubicin/carboplatin was evaluated as first-line therapy for extensive-stage SCLC. Patients received amrubicin (30 mg/m2 daily on days 1, 2, and 3), carboplatin (AUC = 5 on day 1), and pegfilgrastim (6 mg subcutaneously) every 21 days for 4 cycles. The overall response rate was 74%, the 1-year survival rate was 38%, and the median survival was 10 months. Based on the current findings, there is no role for amrubicin as first-line treatment for SCLC.